// App-Quantinova.ai

309 : Phase I study of the novel pro-drug MIV-818 in patients with hepatocellular carcinoma, intra-hepatic cholangiocarcinoma or liver metastases.

Researchers

Presenter

  • T.R. Jeffry Evans

Principal Investigators

  • Eric Van Cutsem

  • Hans Prenen

  • Mark R. Middleton

  • Debashis Sarker

  • Karin Tunblad

  • Fredrik Oberg

  • Tom Morris

  • Linda Basse

  • Elizabeth Ruth Plummer

Medical Centers

  • University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium

  • University Hospital Antwerp (UZ Antwerp), Antwerp, Belgium

  • Churchill Hospital, Oxford, United Kingdom

  • King's College Hospital, Institute of Liver Studies, London, United Kingdom

  • Medicin, Stockholm, Sweden.

  • Medivir AB, Huddinge, Sweden

  • Northern Centre for Cancer Care, Newcastle upon Tyne, United Kingdom

Locations

  • United Kingdom

  • Belgium

  • Sweden

Companies

  • N/A

Study Components

Therapeutic Area

  • Genetic Disorder

Disease

  • Advanced biliary tract carcinoma

  • Liver cancer

  • Secondary liver cancer

  • Solid malignancies

  • Convulsions, familial infantile, with paroxysmal choreoathetosis

Biomarkers

  • N/A

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Dose Escalation

  • Cohort

Phase

  • I

Study Id's

  • NCT03781934

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved